Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: Long-term follow-up of the first 285 reported to the National Marrow Donor Program

被引:55
作者
Giralt, Sergio
Logan, Brent
Rizzo, Douglas
Zhang, Mei-Je
Ballen, Karen
Emmanouilides, Christos
Nath, Rajneesh
Parker, Pablo
Porter, David
Sandmaier, Brenda
Waller, Edmund K.
Barker, Juliet
Pavletic, Steven
Weisdorf, Daniel
机构
[1] Ctr Int Blood & Marrow Transplant Res, Nonmyeloablat Study Grp, Minneapolis, MN USA
[2] Natl Marrow Donor Program, Minneapolis, MN USA
关键词
unrelated donor stem cell transplantation; long-term outcomes; reduced-intensity conditioning regimens;
D O I
10.1016/j.bbmt.2007.03.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine the long-term outcome of patients undergoing unrelated donor transplantation (URD) after a reduced intensity conditioning (RIC) regimen, we performed a retrospective analysis of the transplant outcomes of the first 5 years of RIC experience as reported to the National Marrow Donor Program (NMDP). Patients were included if they were older than 18 years and had undergone a URD transplant procured through the NMDP from january 1, 1996 until May 31, 2001, with an RIC regimen for a hematologic malignancy. The number of URDs performed using an RIC increased from 59 during 1996 to 1999, to 149 in the year 2000. RIC recipients were older (53 vs. 3 3 years) and had a higher likelihood of having advanced disease (8 1% vs. 51%) when compared to patients undergoing a myeloblative conditioning regimen during the same time period. The 5-year survival rate is 23% (95% confidence interval [CI]; 18, 28), whereas the 5 year incidence of progression/relapse is 43.4% (95% Cl; 37,49). Prognostic factors for better overall survival on multivariate analysis were earlier disease stage, longer time to transplant from diagnosis, better HLA, match, >= 90% performance score, and use of peripheral blood stem cells. This analysis demonstrates that long-term survival and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning. However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials. (c) 2007 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:844 / 852
页数:9
相关论文
共 43 条
  • [11] COX DR, 1972, J R STAT SOC B, V34, P187
  • [12] Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
    de Lima, M
    Anagnostopoulos, A
    Munsell, M
    Shahjahan, M
    Ueno, N
    Ippoliti, C
    Andersson, BS
    Gajewski, J
    Couriel, D
    Cortes, J
    Donato, M
    Neumann, J
    Champlin, R
    Giralt, S
    [J]. BLOOD, 2004, 104 (03) : 865 - 872
  • [13] DIACONESCU R, 2003, BLOOD, V102
  • [14] Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors
    Ferrara, JLM
    [J]. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (03): : 299 - 306
  • [15] Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
    Gajewski, JL
    Phillips, GL
    Sobocinski, KA
    Armitage, JO
    Gale, RP
    Champlin, RE
    Herzig, RH
    Hurd, DD
    Jagannath, S
    Klein, JP
    Lazarus, HM
    McCarthy, PL
    Pavlovsky, S
    Petersen, FB
    Rowlings, PA
    Russell, JA
    Silver, SM
    Vose, JM
    Wiernik, PH
    Bortin, MM
    Horowitz, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 572 - 578
  • [16] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [17] Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    Giralt, S
    Thall, PF
    Khouri, I
    Wang, XM
    Braunschweig, I
    Ippolitti, C
    Claxton, D
    Donato, M
    Bruton, J
    Cohen, A
    Davis, M
    Andersson, BS
    Anderlini, P
    Gajewski, J
    Kornblau, S
    Andreeff, M
    Przepiorka, D
    Ueno, NT
    Molldrem, J
    Champlin, R
    [J]. BLOOD, 2001, 97 (03) : 631 - 637
  • [18] Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
  • [19] 2-F
  • [20] BASIC RADIOBIOLOGY
    HALL, EJ
    ASTOR, M
    BEDFORD, J
    BOREK, C
    CURTIS, SB
    FRY, M
    GEARD, C
    HEI, T
    MITCHELL, J
    OLEINICK, N
    RUBIN, J
    TU, A
    ULLRICH, R
    WALDREN, C
    WARD, J
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (03): : 220 - 252